StockIQpro
NASDAQ:KRRO

Korro Bio, Inc.

Track all markets on TradingView
Track all markets on TradingView

Korro Bio, Inc.'s revenue grew 181.5% in fiscal 2025 to $6.4M while operating margin rose to −1906.4%. Free cash flow was −$79.1M, −1237.2% of revenue, and the diluted share count rose 5.3%.Summary generated from Korro Bio, Inc.'s SEC filings. Latest annual report filed Mar 12, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$6.4M
Revenue growth+181.5%
Revenue, 5-yr CAGR−29.6%
Gross marginn/a
Operating margin−1906.4%
Net margin−1834.5%
ROICn/a
Return on equity−110.7%
Debt / equityn/a
Free cash flow−$79.1M
FCF margin−1237.2%
Share count change+5.3%

Financials

Fiscal years, $M
Item20212022202320242025
Revenue140026
Operating income−84−59−85−92−122
Net income−85−58−81−84−117
Free cash flow−79−59−75−78−79

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations